Use of a pharmaceutically acceptable oxalate derivative for the

Details Use of a pharmaceutically acceptable oxalate derivative for the Use of a pharmaceutically acceptable oxalate derivative for the

1997-11-19

2000-09-05

Jarvis, William R. A.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

A61K 3119

Patent

active

061143898

DESCRIPTION:

BRIEF SUMMARY
BACKGROUND OF THE INVENTION

The present invention relates to the use of compositions foe the treatment of conditions, disorders or diseases of the skin, the autoimmune system or the respiratory tract, or conditions, disorders or diseases associated therewith, which comprise a pharmaceutically acceptable oxalate and a pharmaceutical acceptable carrier. The pharmaceutically acceptable oxalate is preferably an oxalate of a group Ia or IIa metal or a transition metal of the first transition series.
In International Patent Application No. WO 94/15574, the present inventor disclosed that oxalates of group Ia or IIa metals could be used for restoring hair loss due to conditions such as alopecia areata. The present inventor has now discovered that inorganic and organic oxalates can also be used to treat conditions, disorders or diseases of the skin, the autoimmune system or the respiratory tract, and associated illnesses, other than those involving hair loss.
In International Patent Application No. WO92/04896, Gerber and Matkovic disclose the use of gallium compounds for treating diseases mediated by macrophage cell lines, including lupus erythematosus, and for prevention of resistance to transplantation. The preferred gallium compounds are selected from the group consisting of gallium nitrate, gallium citrate, gallium chloride, gallium carbonate, gallium acetate, gallium lactate, gallium tartrate, gallium oxalate, gallium oxide and hydrated gallium oxide. Of these compounds, gallium nitrate is especially favoured.


SUMMARY OF THE INVENTION

Accordingly, in a first aspect of the invention, there is provided the use of a composition comprising a pharmaceutically acceptable oxalate and a pharmaceutically acceptable carrier in the manufacture of a medicament for use in a method of treating an immunologically-mediated condition, disorder or disease of the skin, the autoimmune system or the respiratory tract, or a condition, disorder or disease associated therewith, wherein said composition does not comprise gallium oxalate when said condition is lupus erythematosus, and does not comprise a group Ia or IIa metal oxalate or ammonium oxalate when said condition is seborrheoa.
In a second aspect of the invention, there is provided a method of treating an immunologically-mediated condition, disorder or disease of the skin, the autoimnune system or the respiratory tract, or a condition, disorder or disease associated therewith, comprising administering to a patent a therapeutically effective amount of a composition comprising a pharmaceutically acceptable oxalate and a pharmaceutically acceptable carrier, wherein said composition does not comprise gallium oxalate when said condition is lupus erythematosus, and does not comprise a group Ia or IIa metal oxalate or ammonium oxalate when said condition is seborrheoa.
In the invention according to its first or second aspects, the conditions, disorders or diseases of the skin which may be treated with the oxalate compositions include psoriasis, eczema, dermatitis, erythema, seborrhoea, lichen planus, lupus erythematosus, herpes simplex, cutaneous manifestations of immunologically mediated diseases, hypoproliferative or inflammatory skin diseases, and related conditions. The more common forms of dermatitis which may be treated by the invention include atopic dermatitis, contact dermatitis and seborrheic dermatitis.
The associated conditions, disorders or diseases which may be treated by the invention include infections, chronic inflammatory diseases and eating-related disorders but are not restricted to such illnesses. Skin conditions are often known to be associated with disorders of the immune system and with diseases of the respiratory tract, such as asthma, and, accordingly, it is envisaged that the present invention may also be of assistance in the treatment of such complaints. In a preferred embodiment, the invention may be used in the treatment of cutaneous asthma, since treatment or any underlying skin complaint may provide relief against asthma caused by flaking or scal

REFERENCES:
patent: 5175006 (1992-12-01), Matkovic et al.
patent: 5639459 (1997-06-01), Bouras
patent: 5648389 (1997-07-01), Gans et al.
Robert Berkow et al.: "The Merck Manual of Diagnosis and Therapy". The Merck Research Laboratories, 1992, 16th Edition, pp. 1317, 2407-2411, 2435, 2441.

Affiliated with

Also associated with

Rating

Use of a pharmaceutically acceptable oxalate derivative for the does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of a pharmaceutically acceptable oxalate derivative for the , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of a pharmaceutically acceptable oxalate derivative for the will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2212630